Lilly Halts Phase 1 Trial of Nectin-4 ADC LY4052031 Due to Safety Concerns

Eli LillyThe First Clinical Trial of LY4052031Paused Due to Safety Concerns., the companyThe First ClauseLY4101174 is still in clinical trials.

Nectin-4 is an immunoglobulin-like antigen that is overexpressed in a variety of cancers, including bladder cancer, breast cancer, non-small cell lung cancer, and gastric cancer. Normal tissues express only low to moderate levels of Nectin-4, making this protein an attractive target for cancer therapy.

LY4052031 is a next-generation Nectin-4-targeted ADC developed internally by Eli Lilly.。LY4052031The antibody also adopts Fc Silence treatment, with the Payload being the topoisomerase inhibitor Camptothecin-98, and a DAR value of 8.

Preclinical studies have shown that LY4052031 exhibits strong cytotoxicity against tumor cells with both high and low expression of Nectin-4.The product is also available in a variety ofNectin-4Showed strong in vivo efficacy in tumor models expressing and resistant to MMNEOverall, LY4052031, as a next-generation therapy for treating Nectin-4 positive tumors, demonstrates specificity, selectivity, potency, and efficacy.

Will continue to follow up.

End

---

Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, with sources and authors clearly attributed. This official account welcomes sharing in friend circles or large groups.Unauthorized reproduction by any media or organization in any form to other platforms is prohibited.。

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more